Kaketsuken Becomes First Japanese Pharmaceutical Company to Implement Medidata Solutions, Inc.’s Integrated Solutions for Randomization, Trial Supply Management and Clinical Data Collection, Management and Reporting in Japanese Trials
10/1/2012 10:19:05 AM
NEW YORK--(BUSINESS WIRE)--Vaccine maker KAKETSUKEN, also known as the Chemo-Sero-Therapeutic Research Institute, has become the first Japanese pharmaceutical company to use the combined capabilities of the Medidata Balance™ randomization and trial supply management (RTSM) solution and Medidata Rave® electronic data capture (EDC), clinical data management and reporting system for a Japanese clinical trial. A leading company in the field of biological products, KAKETSUKEN will use the Medidata Solutions (NASDAQ: MDSO) platform to reduce time, costs and risk in a Phase II clinical trial testing a vaccine, and plans to use the solutions for other future trials.
comments powered by